Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Saved in:
| Title: | Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. |
|---|---|
| Authors: | Wang YW; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan., Tsai XC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. xavierchtsai@ntu.edu.tw., Hou HA; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tien FM; Department of Hematological Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan., Liu JH; Department of Hematological Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan., Chou WC; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan., Ko BS; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan., Chen YW; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan., Lin CC; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan., Cheng CL; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Lo MY; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Lin YC; Department of Hematological Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan., Lu LC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Wu SJ; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Kuo SH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Hong RL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Huang TC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Yao M; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. yaoming@ntu.edu.tw. |
| Source: | Annals of hematology [Ann Hematol] 2022 Feb; Vol. 101 (2), pp. 349-358. Date of Electronic Publication: 2021 Nov 11. |
| Publication Type: | Clinical Trial; Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-021-04711-9 |
